In our meta-analysis, SPRY4-IT1 expression levels were obviously upregulated in colorectal cancer, cervical cancer, hepatocellular carcinoma, ovarian cancer, melanoma, gastric cancer, breast cancer, esophageal squamous cell carcinoma, renal cell carcinoma, bladder cancer, cholangiocarcinoma, pancreatic ductal adenocarcinoma, glioma, and lung adenocarcinoma but downregulated in NSCLC. Here, SPRY4 is linked to ovarian cancer.